Hims & Hers Health (NYSE:HIMS) CFO Sells $219,088.09 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 9,217 shares of Hims & Hers Health stock in a transaction on Friday, March 20th. The stock was sold at an average price of $23.77, for a total transaction of $219,088.09. Following the transaction, the chief financial officer directly owned 318,789 shares of the company’s stock, valued at approximately $7,577,614.53. This trade represents a 2.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Oluyemi Okupe also recently made the following trade(s):

• On Tuesday, January 20th, Oluyemi Okupe sold 9,067 shares of Hims & Hers Health stock. The shares were sold at an average price of $30.34, for a total transaction of $275,092.78.
• On Monday, January 5th, Oluyemi Okupe sold 9,070 shares of Hims & Hers Health stock. The shares were sold at an average price of $33.79, for a total transaction of $306,475.30.

Hims & Hers Health Stock Performance

NYSE HIMS opened at $19.43 on Friday. The firm has a 50-day moving average of $21.73 and a 200-day moving average of $35.87. The company has a debt-to-equity ratio of 1.80, a quick ratio of 1.70 and a current ratio of 1.90. The stock has a market cap of $4.43 billion, a PE ratio of 38.09, a P/E/G ratio of 2.51 and a beta of 2.55. Hims & Hers Health, Inc. has a 52-week low of $13.74 and a 52-week high of $70.43.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, February 23rd. The company reported $0.08 EPS for the quarter, beating analysts’ consensus estimates of $0.02 by $0.06. The business had revenue of $617.82 million for the quarter, compared to analyst estimates of $619.48 million. Hims & Hers Health had a net margin of 5.47% and a return on equity of 22.48%. Hims & Hers Health’s quarterly revenue was up 28.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.11 EPS. On average, sell-side analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on HIMS. Weiss Ratings reiterated a “hold (c)” rating on shares of Hims & Hers Health in a research note on Monday, December 29th. Bank of America raised Hims & Hers Health from an “underperform” rating to a “neutral” rating and upped their price objective for the company from $12.50 to $23.00 in a report on Tuesday, March 10th. Needham & Company LLC upgraded Hims & Hers Health from a “hold” rating to a “buy” rating and set a $30.00 price objective on the stock in a research report on Monday, March 9th. Zacks Research raised Hims & Hers Health from a “strong sell” rating to a “hold” rating in a report on Wednesday, February 25th. Finally, TD Cowen reduced their target price on shares of Hims & Hers Health from $25.00 to $23.00 and set a “hold” rating for the company in a research report on Friday. Three equities research analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $31.71.

Institutional Investors Weigh In On Hims & Hers Health

Institutional investors have recently made changes to their positions in the stock. Virtus Advisers LLC acquired a new stake in Hims & Hers Health during the second quarter worth approximately $26,000. Quent Capital LLC acquired a new position in Hims & Hers Health in the 3rd quarter valued at $28,000. Flagship Harbor Advisors LLC bought a new stake in shares of Hims & Hers Health during the 4th quarter valued at $28,000. Binnacle Investments Inc bought a new stake in shares of Hims & Hers Health during the 3rd quarter valued at $28,000. Finally, Bogart Wealth LLC grew its holdings in shares of Hims & Hers Health by 235.8% during the 4th quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock worth $29,000 after purchasing an additional 632 shares in the last quarter. 63.52% of the stock is currently owned by institutional investors.

Key Stories Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Major commercial catalyst — HIMS announced availability of a broad suite of Novo Nordisk FDA‑approved GLP‑1 medications for eligible customers, expanding product mix and potential revenue/ARPU upside from higher‑price branded drugs. Novo Nordisk’s FDA-Approved GLP-1s Now Available With Hims & Hers
• Positive Sentiment: Business model shift — coverage highlights HIMS moving toward a broader mix of branded, FDA‑approved GLP‑1s after the Novo collaboration and FDA shortage resolution, which could lift margins and reduce prior legal/commercial uncertainty. Hims & Hers shifts business model after Novo deal
• Neutral Sentiment: Analyst/features coverage and investor writeups (Seeking Alpha, USA Today sponsored pieces, Yahoo/Fool commentary) are framing a potential reset and longer‑term inflection, useful for context but not immediate proof of sustained upside. Hims & Hers: The Reset Before The Next Inflection
• Neutral Sentiment: Institutional positions remain large (Vanguard, Capital World, Farallon, etc.), which supports liquidity and means any moves could be amplified by institutional flows rather than retail noise. MarketBeat HIMS Coverage
• Negative Sentiment: Fresh analyst pressure — TD Cowen trimmed its price target to $23 and set a “hold”, and other outlets report lower targets/discounted valuations, which can trigger short‑term selling and lower investor conviction. TD Cowen price target cut (Benzinga)
• Negative Sentiment: Legal and governance overhang — a securities‑fraud investigation has been opened (Schall Law Firm), creating regulatory risk that can depress multiples until resolved. Fraud investigation announcement
• Negative Sentiment: Insider selling — CFO Oluyemi Okupe sold ~9.2k shares recently; continued insider sales have been flagged by analysts and can sap market confidence, especially amid valuation compression. SEC Form 4 — Insider Sale

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.